Moreover, genetic studies are revealing novel drug targets such as PCSK9. It was initially reported that PCSK9 nonsense mutation carriers had lower plasma levels of LDL cholesterol and a significantly reduced risk of coronary heart disease (Horton et al., 2007). Here, PCSK9 is linked to coronary artery disorder.